|
1
|
Ito Y, Nikiforov YE, Schlumberger M and
Vigneri R: Increasing incidence of thyroid cancer: Controversies
explored. Nat Rev Endocrinol. 9:178–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kilfoy BA, Zheng T, Holford TR, Han X,
Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al:
International patterns and trends in thyroid cancer incidence,
1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: Update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A national cancer data base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995 [see commetns].
Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Omur O and Baran Y: An update on molecular
biology of thyroid cancers. Crit Rev Oncol Hematol. 90:233–252.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang IC, Chou FF, Liu RT, Tung SC, Chen
JF, Kuo MC, Hsieh CJ and Wang PW: Long-term outcomes of distant
metastasis from differentiated thyroid carcinoma. Clin Endocrinol
(Oxf). 76:439–447. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kebebew E, Weng J, Bauer J, Ranvier G,
Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence
and prognostic value of BRAF mutation in thyroid cancer. Ann Surg.
246:466–471. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen WT, Ogawa L, Ruan D, Suh I, Duh QY
and Clark OH: Central neck lymph node dissection for papillary
thyroid cancer: The reliability of surgeon judgment in predicting
which patients will benefit. Surgery. 148:398–403. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baek SK, Jung KY, Kang SM, Kwon SY, Woo
JS, Cho SH and Chung EJ: Clinical risk factors associated with
cervical lymph node recurrence in papillary thyroid carcinoma.
Thyroid. 20:147–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dorn R, Kopp J, Vogt H, Heidenreich P,
Carroll RG and Gulec SA: Dosimetry-guided radioactive iodine
treatment in patients with metastatic differentiated thyroid
cancer: Largest safe dose using a risk-adapted approach. J Nucl
Med. 44:451–456. 2003.PubMed/NCBI
|
|
12
|
Wartofsky L, Sherman SI, Gopal J,
Schlumberger M and Hay ID: The use of radioactive iodine in
patients with papillary and follicular thyroid cancer. J Clin
Endocrinol Metab. 83:4195–4203. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhaijee F and Nikiforov YE: Molecular
analysis of thyroid tumors. Endocr Pathol. 22:126–133. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nikiforov YE: Molecular analysis of
thyroid tumors. Mod Pathol. 24 Suppl 2:S34–S43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Henderson BE and Feigelson HS: Hormonal
carcinogenesis. Carcinogenesis. 21:427–433. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen GG, Vlantis AC, Zeng Q and van
Hasselt CA: Regulation of cell growth by estrogen signaling and
potential targets in thyroid cancer. Curr Cancer Drug Targets.
8:367–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rahbari R, Zhang L and Kebebew E: Thyroid
cancer gender disparity. Future Oncol. 6:1771–1779. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kansakar E, Chang YJ, Mehrabi M and Mittal
V: Expression of estrogen receptor, progesterone receptor, and
vascular endothelial growth factor-A in thyroid cancer. Am Surg.
75:785–789. 2009.PubMed/NCBI
|
|
19
|
Lee HR, Kim TH and Choi KC: Functions and
physiological roles of two types of estrogen receptors, ERα and
ERβ, identified by estrogen receptor knockout mouse. Lab Anim Res.
28:71–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng Q, Chen GG, Vlantis AC and van
Hasselt CA: Oestrogen mediates the growth of human thyroid
carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif.
40:921–935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Inoue T, Kon T, Ohkura R, Yamakawa H,
Ohara O, Yokota J and Sutoh K: BREK/LMTK2 is a myosin VI-binding
protein involved in endosomal membrane trafficking. Genes Cells.
13:483–495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Naik S, Dothager RS, Marasa J, Lewis CL
and Piwnica-Worms D: Vascular endothelial growth factor receptor-1
is synthetic lethal to aberrant {beta}-catenin activation in colon
cancer. Clin Cancer Res. 15:7529–7537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tyner JW, Deininger MW, Loriaux MM, Chang
BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T,
Heinrich MC and Druker BJ: RNAi screen for rapid therapeutic target
identification in leukemia patients. Proc Natl Acad Sci USA.
106:8695–8700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giamas G, Filipović A, Jacob J, Messier W,
Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, et
al: Kinome screening for regulators of the estrogen receptor
identifies LMTK3 as a new therapeutic target in breast cancer. Nat
Med. 17:715–719. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nikiforov YE: Molecular diagnostics of
thyroid tumors. Arch Pathol Lab Med. 135:569–577. 2011.PubMed/NCBI
|
|
26
|
Shi H, Li Q, Ji M, Wu J, Li Z, Zheng X, Xu
B, Chen L, Li X, Lu C, et al: Lemur tyrosine kinase-3 is a
significant prognostic marker for patients with colorectal cancer.
Int J Clin Exp Pathol. 7:1101–1107. 2014.PubMed/NCBI
|
|
27
|
Stebbing J, Filipovic A, Ellis IO, Green
AR, D'Silva TR, Lenz HJ, Coombes RC, Wang T, Lee SC and Giamas G:
LMTK3 expression in breast cancer: Association with tumor phenotype
and clinical outcome. Breast Cancer Res Treat. 132:537–544. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Z, Wu J, Ji M, Shi L, Xu B, Jiang J and
Wu C: Prognostic role of lemur tyrosine kinase 3 in postoperative
gastric cancer. Mol Clin Oncol. 2:756–760. 2014.PubMed/NCBI
|
|
29
|
Fan Y, Chen M, Meng J, Yu L, Tu Y, Wan L,
Fang K and Zhu W: Arsenic trioxide and resveratrol show synergistic
anti-leukemia activity and neutralized cardiotoxicity. PLoS One.
9:e1058902014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi H, Wu J, Ji M, Zhou Q, Li Z, Zheng X,
Xu B, Deng H, Zhao W, Wu C and Jiang J: Serum lemur tyrosine kinase
3 expression in colorectal cancer patients predicts cancer
progression and prognosis. Med Oncol. 30:7542013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Z, Qi X, Zhang X and Yu L: Preoperative
serum LMTK3 as a novel biomarker in non-small cell lung cancer.
Tumour Biol. 35:5007–5011. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao G, Guo J, Li D, Jia C, Yin W, Sun R,
Lv Z and Cong X: MicroRNA-34a suppresses cell proliferation by
targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell
Biol. 32:699–707. 2013. View Article : Google Scholar : PubMed/NCBI
|
